Clinical Trial of Mifepristone for Bipolar Depression

June 30, 2017 updated by: National Institute of Mental Health (NIMH)

Antiglucocorticoid Therapy in Bipolar Depression With Mifepristone (RU486)

Bipolar Depression is a severe illness with high rates of psychiatric comorbidity and increased mortality related to suicide and medical illness. Hypothalamic pituitary axis (HPA) hyperactivity are found in bipolar disorder related to depression and mixed states. Patients with bipolar disorder also have cognitive difficulties and endocrine disturbances may contribute to such dysfunction. Antiglucorticoid therapies are novel treatments of mood disorder. Preliminary data in psychotic depression suggesting that mifepristone (RU-486), a glucocorticoid receptor antagonist, has antidepressant and salutary cognitive effects in a matter of days. In this study we examine the effects of mifepristone in severe bipolar depression in a parallel, double blind placebo controlled experiment. Bipolar subjects maintained on either lithium or valproate, after washout or prior antidepressants have a detailed neuroendocrine assessment. Patients approximately or almost 75 will receive eight days of mifepristone versus placebo after which patients are blindly crossed over to the opposite arm. Patients and a group of matched controls approximately or almost 35 will be compared with neuroendocrine, cognitive, and neurophysiologic testing to fully characterize their phenotype and explore biomarkers of response. It is hypothesized that stigmata of HPA axis hyperactivity and cognitive impairment will be predictive of response to antiglucocorticoid therapy with mifepristone.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Bipolar Depression is a severe illness with high rates of psychiatric comorbidity and increased mortality related to suicide and medical illness. Hypothalamic pituitary axis (HPA) hyperactivity are found in bipolar disorder related to depression and mixed states. Patients with bipolar disorder also have cognitive difficulties and endocrine disturbances may contribute to such dysfunction. Antiglucorticoid therapies are novel treatments of mood disorder. Preliminary data in psychotic depression suggesting that mifepristone (RU-486), a glucocorticoid receptor antagonist, has antidepressant and salutary cognitive effects in a matter of days. In this study we examine the effects of mifepristone in severe bipolar depression in a parallel, double blind placebo controlled experiment. Bipolar subjects maintained on either lithium or valproate, after washout or prior antidepressants have a detailed neuroendocrine assessment. Patients approximately or almost 75 will receive eight days of mifepristone versus placebo after which patients are blindly crossed over to the opposite arm. Patients and a group of matched controls approximately or almost 35 will be compared with neuroendocrine, cognitive, and neurophysiologic testing to fully characterize their phenotype and explore biomarkers of response. It is hypothesized that stigmata of HPA axis hyperactivity and cognitive impairment will be predictive of response to antiglucocorticoid therapy with mifepristone.

Study Type

Interventional

Enrollment

110

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Pennsylvania
      • Philadelphia, Pennsylvania, United States, 19104-6056
        • University of Pennsylvania

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

  • HEALTHY VOLUNTEERS ARE CURRENTLY NOT BEING RECRUITED FOR THIS STUDY.

INCLUSION CRITERIA FOR BIPOLAR PATIENTS:

Patients must meet the following inclusion criteria in order to participate in the study:

  1. Male or female inpatients in need of treatment for severe bipolar depression.
  2. 18-75 years of age.
  3. Women of childbearing potential must be using an adequate form of contraception as defined by one of the following: 1) a barrier method and 2) oral contraceptives plus a barrier method (women who are on an OCP will be kept on it others must agree to use only a barrier method).
  4. DSM-IV diagnosis of bipolar depression I/II, severe, with or without psychotic features.
  5. A current major depressive episode of at least 6 weeks' duration.
  6. Score of greater than or equal to 18 on the first 17-item HAM-D at the prestudy visit and at the first baseline phase visit.
  7. Score of 15 or greater on the HAM-D (17) at the end of the baseline period(s) (i.e., at randomization no more than 20% less than entry enrollment criteria).
  8. Score of greater than or equal to 4 on the CGI-BP scale at the prestudy and first visit and end of baseline phase.
  9. Judged to be in good physical health on the basis of medical history, physical examination, and laboratory screening.
  10. Able to understand procedures and agree to participate in the study by giving written informed consent.
  11. On lithium and/or valproate for at least 4 weeks (2 levels, 1 wk apart)
  12. However patients not on a mood stabilizer can have this started as an outpatient or inpatient for 4 weeks as discussed above.
  13. Able to come off of prior drugs and PRN zolpidem and lorazepam by start of baseline.

EXCLUSION CRITERIA FOR BIPOLAR PATIENTS:

Patients will be excluded from the study if they meet any of the following criteria:

  1. Women who are pregnant, intending to become pregnant in the next month or breast-feeding.
  2. Treatment with any of the following therapies within the specified interval prior to baseline: Fluoxetine - 4 weeks; Investigational compounds 4 weeks; MAOIs 1 week; Other antidepressants 1 week.
  3. Contraindication or history of hypersensitivity to mifepristone as well as cortisol, and CRH.
  4. Clinically significant organ system disease where mifepristone would be contraindicated or interfere with medical treatment.
  5. Have evidence of any disorder that represents a contraindication to the use of mifepristone (such as adrenal disease or a condition requiring chronic corticosteroid administration).
  6. History of Addison's Disease, Cushing's Disease, insulin dependent diabetes, or other uncompensated endocrine conditions.
  7. Evidence of infection, severe liver, respiratory, or renal disease.
  8. Have clinically significant cardiovascular disease, e.g., angina, valve disease, arrhythmia, cardiac failure.
  9. Anemia (hemoglobin less than 10 g/dL or hematocrit less than 30%)
  10. Have a known clotting defect or are receiving anticoagulants.
  11. Rapid cycling in the last year (defined as greater than 6 episodes).
  12. History of porphyrias.
  13. Clinically significant abnormalities in physical exam, ECG, or laboratory assessments.
  14. History of any disease which, in the investigator's opinion may confound the results of the study or pose an additional risk, including but not limited to, history of organic mental disorder, seizures, or mental retardation.
  15. Substance dependence that is not in sustained full remission (DSM-IV definition)
  16. Other principal psychiatric diagnosis judged by the investigator to dominate the clinical presentation. In particular, patients with depressive symptoms more than 2 years in duration should be carefully evaluated to determine whether another psychiatric diagnosis exists which could interfere with efficacy and safety measurements.
  17. History of nonresponse to greater than four trials of antidepressants for the current episode (not including mood stabilizers) will exclude subjects.

INCLUSION CRITERIA FOR NORMAL CONTROLS:

  1. SCID-NP- no psychiatric diagnosis lifetime.
  2. Ages 18-75.
  3. Medically and psychiatrically healthy by history and no disallowed medications for 2 weeks, and agrees to no alcohol use for 1 week baseline period of study.
  4. No history of mood or anxiety disorder in first-degree relatives.
  5. Women of childbearing potential must be using adequate form of contraception as defined by one of the following: 1) a barrier method and 2) oral contraceptives plus a barrier method.

EXCLUSION CRITERIA FOR NORMAL CONTROLS:

  1. Known hypersensitivity to CRH, hydrocortisone, metyrapone, or mifepristone.
  2. Women who are pregnant or breast-feeding.
  3. Clinically significant organ system disease where mifepristone would be contraindicated or interfere with medical treatment.
  4. History of prophyrias.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

National Institute of Mental Health (NIMH)

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

August 7, 2002

Study Completion

June 25, 2007

Study Registration Dates

First Submitted

August 9, 2002

First Submitted That Met QC Criteria

August 9, 2002

First Posted (Estimate)

August 12, 2002

Study Record Updates

Last Update Posted (Actual)

July 2, 2017

Last Update Submitted That Met QC Criteria

June 30, 2017

Last Verified

June 25, 2007

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 020251
  • 02-M-0251

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Bipolar Disorder

Clinical Trials on Mifepristone

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Croatia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe